Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate. The antibody is a humanised anti-TROP2 IgG1 attached to deruxtecan, a topoisomerase I inhibitor (DXd) bound by a tetrapeptide-based cleavable linker. The antibody-drug conjugate is stable in plasma. The antibody binds to TROP2 expressed on the surface of certain tumour cells. After binding, datopotamab deruxtecan undergoes internalisation into the tumour cells. Subsequently, the release of DXd results in DNA damage and apoptotic cell death via topoisomerase I inhibition.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| L01FX35 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| DATROWAY Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) |
Datopotamab deruxtecan is an active ingredient of these brands:
Lithuania (LT)United States (US)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.